Nunn Jason Raleigh

SEC Form 4 insider trading activity

Nunn Jason Raleigh has filed 2 SEC Form 4 filings (3 transaction rows) across 2 companies, including ADXN, ZBIO, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Sep 4, 2026.

On the most recent filing, Nunn Jason Raleigh is listed as Director at Zenas BioPharma, Inc. Inside the rolling window, Nunn Jason Raleigh reported 1 open-market purchase totaling $1.2M in ZBIO and no open-market sales.

Companies traded

Other insiders at ADXN

Insider Buying

$1.2M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

2

in the rolling window

Source
ZBIO
Nunn Jason Raleigh
Purchase$1.2MOct 14SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Nunn Jason Raleigh made?

Nunn Jason Raleigh has filed 2 SEC Form 4 filings (3 transaction rows) across 2 companies, including ADXN, ZBIO since 2025.

Which companies does Nunn Jason Raleigh trade?

Nunn Jason Raleigh has filed SEC Form 4 disclosures for 2 companies, including ADXN, ZBIO.

When was Nunn Jason Raleigh's most recent SEC Form 4 filing?

Nunn Jason Raleigh's most recent SEC Form 4 filing on Tracefour is dated Sep 4, 2026.

What is Nunn Jason Raleigh's total buy and sell value in the current window?

Inside the rolling retention window, Nunn Jason Raleigh bought $1.2M and sold $0 based on SEC Form 4 filings.

What was Nunn Jason Raleigh's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 63,158 ZBIO shares on 2025-10-09, worth $1.2M, per SEC Form 4 filings.